AlloVir Inc.

18.75+0.7800+4.34%Vol 174.76K1Y Perf -26.27%
Jul 23rd, 2021 16:00 DELAYED
BID18.82 ASK18.83
Open18.16 Previous Close17.97
Pre-Market- After-Market-
 - -  - -%
Target Price
48.50 
Analyst Rating
— — 0.00
Potential %
158.67 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap1.22B 
Earnings Rating
Price Range Ratio 52W %
6.47 
Earnings Date
1st Sep 2021

Today's Price Range

17.7318.96

52W Range

16.6648.96

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
6.35%
1 Month
-11.14%
3 Months
-16.07%
6 Months
-56.08%
1 Year
-26.27%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALVR18.750.78004.34
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.40-0.50-25.00
Q03 2020-0.33-0.58-75.76
Q02 2020-0.32-4.43-1 284.38
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date1st Sep 2021
Estimated EPS Next Report-0.45
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume174.76K
Shares Outstanding65.11M
Trades Count3.36K
Dollar Volume7.14M
Avg. Volume303.61K
Avg. Weekly Volume229.35K
Avg. Monthly Volume196.04K
Avg. Quarterly Volume234.43K

AlloVir Inc. (NASDAQ: ALVR) stock closed at 18.75 per share at the end of the most recent trading day (a 4.34% change compared to the prior day closing price) with a volume of 174.76K shares and market capitalization of 1.22B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. AlloVir Inc. CEO is David Hallal.

The one-year performance of AlloVir Inc. stock is -26.27%, while year-to-date (YTD) performance is -51.22%. ALVR stock has a five-year performance of %. Its 52-week range is between 16.66 and 48.96, which gives ALVR stock a 52-week price range ratio of 6.47%

AlloVir Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 17.85, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -38.07%, a ROC of -39.92% and a ROE of -41.21%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from AlloVir Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.45 for the next earnings report. AlloVir Inc.’s next earnings report date is 01st Sep 2021.

The consensus rating of Wall Street analysts for AlloVir Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for AlloVir Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AlloVir Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AlloVir Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.06, ATR14 : 1.11, CCI20 : -30.62, Chaikin Money Flow : -0.05, MACD : -0.88, Money Flow Index : 37.60, ROC : 0.21, RSI : 46.51, STOCH (14,3) : 62.76, STOCH RSI : 1.00, UO : 54.18, Williams %R : -37.24), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AlloVir Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

AlloVir Inc.

AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.

CEO: David Hallal

Telephone: +1 617 433-2605

Address: 139 Main Street, Cambridge 02142, MA, US

Number of employees: 53

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

31%69%

Bearish Bullish

56%44%

Bearish Bullish

67%33%

News

Stocktwits